MedPath

Role of Individualized Homoeopathic medicine in treatment of seborrheic dermatitis and its impact on quality of life a single arm pre post clinical study

Phase 2
Conditions
Health Condition 1: L219- Seborrheic dermatitis, unspecified
Registration Number
CTRI/2024/05/067321
Lead Sponsor
ational Institute of Homoeopathy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

(a) Clinically diagnosed cases of SD (ICD-10 code- L29.1)

(b) Aged between 20 – 60 years and all genders.

(c) Patients not receiving any topical treatment for SD on last 3 months.

(d) Patients who can read and/or understand either Hindi or English or Bengali.

(e) Patients who are willing to give consent

Exclusion Criteria

(a) Pregnant and lactating women.

(b) Associated systemic or immune compromised illness.

(c) Patients under other medications for any chronic disease.

(d) Diagnosed cases of any life threatening, malignant or psychiatric diseases.

(e) Simultaneous participation in any other clinical trials

(f) Substance abuse and/or dependence

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
SDASI; SDASI is a scoring system used for assessment of SD. Parts of the body affected <br/ ><br>with SD are examined in the patients and grading for erythema, papule and scale. <br/ ><br>Assessment of the degree of erythema (E), papules (P). and scales (S) on each area <br/ ><br>• Determination of the local area score on each area, which is the percentage of SD <br/ ><br>symptom on the affected area are compared to the surrounding area <br/ ><br>• Calculation of SDASI score of each area is done with the equation <br/ ><br> (E+P+S) × Local Area Score <br/ ><br>• Quantification of all three SDASI scores <br/ ><br>• Classification of SD severity according to the SDASI score <br/ ><br>Timepoint: At baseline and after 6 months
Secondary Outcome Measures
NameTimeMethod
SKINDEX 29Timepoint: At baseline and after 6months
© Copyright 2025. All Rights Reserved by MedPath